Rolandic epilepsy (RE), or benign epilepsy of childhood with centrotemporal spikes (BECT), is the most frequent idiopathic partial epilepsy syndrome of childhood, where the "idiopathic" implies a genetic predisposition. Although RE has long been presumed to have a genetic component, clinical and genetic studies have shown a complex inheritance pattern. Furthermore, the underlying major genetic influence in RE has been challenged by recent reports of twin studies. Meanwhile, many genes or loci have been shown to be associated the RE/atypical RE (ARE) spectrum, with a higher frequency of causative variants in ARE. However, a full understanding of the genetic basis in the more common forms of the RE spectrum remains elusive.
Introduction
Rolandic epilepsy (RE), also known as benign epilepsy with centrotemporal spikes (BECT), accounts for about 10-20% of childhood epilepsy [1] [2] [3] . The age of onset of RE is typically 3-13 years, with a peak incidence between 7-9 years old, and invariably shows remission by 14 years [4] . The core clinical characteristics include a focal seizure with sensorimotor symptoms, involving the face and laryngeal muscle, or secondary generalized tonic-clonic seizures, mainly during sleep. Characteristic centrotemporal spikes (CTS) and typical seizures are sufficient for diagnosis. The prognosis of RE is relatively benign, as the name indicates; however, moderate behavior and learning problems may exist in some patients. Compared to typical RE, atypical RE (ARE) includes atypical benign partial epilepsy (ABPE), Landau-Kleffner syndrome (LKS), and epileptic encephalopathy with continuous spikeand-waves during sleep (CSWS), which are at the severe end of the clinical spectrum of epileptic disorders with speech and language dysfunction. Most RE patients do not show a simple Mendelian inheritance pattern; therefore, the genetic origin of RE has been the subject of much speculation but remains but remains largely unknown. Given their overlapping clinical characteristics, RE and ARE are presumed to have a shared genetic etiology. In this review, we will concentrate on RE, the most common disease in the spectrum, and the recent research progress on its genetic basis, as well as some promising new genes or loci that might act as scientific resources to guide future research.
Confusing clinical genetic studies

Family aggregation
Family aggregation, the phenomenon of a high percentage of epilepsy in close relatives, has long been found in RE, suggesting a case for pathogenic genes in RE. The first article reporting family aggregation was published in 1964, with a family history of more than 10% convulsions or epilepsy in RE [5] . The concept of a major genetic basis for RE received support from studies in the 1960s-1990s that showed a positive family history of patients with RE ranging from 3.5% to 59% [4, [6] [7] [8] [9] [10] [11] . Later, one study reported that families of patients with RE showed no aggregation of Rolandic epilepsy, but did show variable seizure types, such as febrile convulsion and generalized tonic-clonic seizures instead [12] , leading to the hypothesis that RE was controlled by a single autosomal dominant gene with age-dependent penetrance and multifactorial inheritance. It is critical to verify the spectrum of clinical manifestations and electroencephalogram (EEG) traits in the family members of patients with RE or CTS without epileptic seizure respectively, to generate hypotheses for further research.
Twin studies
In the pre-genetic era, twin studies were a powerful tool to study the genetic influence on diseases. Although RE was thought to be a genetically influenced disease, twin studies revealed another side to the story. The small number of cases of RE twins meant that the few case reports demonstrated that the concordance rate in RE (4/8) was lower than that in the presence of CTS (6/ 6), which made the hereditary nature of CTS and RE, or the linkage between them, more complicated [13] [14] [15] [16] [17] [18] . An RE study of eight twins based on a twin database later demonstrated, for the first time, that there was no concordance for CTS or RE (0/6 in homozygous twins and 0/2 in dizygous twins), which was a striking finding arguing for the auto-dominant trait of RE [19] . Two years later, the same team provided more evidence from a study of another 10 twins with RE from other twin registries, which also showed zero concordance [20] . The gap between the twin studies and molecular testing was so large that could not be easily explained by environmental factors, somatic mutations, or epigenetic influences. Comprehensive genetic sequencing of twin patients might permit significant progress in understanding the underlying pathophysiological mechanisms.
Loci linkage on CTS
Focal sharp waves in the centrotemporal area, called centrotemporal spikes or CTS, are the primary EEG characteristics of RE or ARE; however, they are also found in healthy children [21] or children with autism spectrum disorder (ASD) without clinical seizures [22] . When comparing investigations of the prevalence of clinical seizures, some family studies, which included the EEG traits in symptom-free relatives, indicated that CTS were was transmitted as an autosomal dominant trait with age-dependent penetrance, with or without male preponderance [5, 23, 24] . However, another study argued for a more complex mode of inheritance [25] , because the detection of CTS was influenced significantly by the age of the subject when the EEG was performed. In addition to the complex clinical genetic studies, genome-wide linkage scans demonstrated linkage of CTS to 16p12-11.2 (logarithm of odds (LOD) 3.68 [26] ), 15q14 (LOD 3.56; [27] ) and 11p13 (LOD 4.30; [28] ) respectively, with the last locus being pleiotropic for speech dyspraxia and CTS in RE [29] .
The inheritance of CTS is clearly not identical to the inheritance of RE. CTS is necessary, but not sufficient, for RE, because only around 10% of children fulfilling the EEG criteria of CTS actually have seizures [23] . The mechanisms that underlie the seizure expression in subjects with CTS and the inheritance of CTS have been mutually exclusive until now.
Genes and loci identified in RE and ARE
To date, a number of genes have been linked to the RE spectrum, with some identified in families with CTS, such as GRIN2A, and some that were identified by genome-wide linkage analysis (GWLS), such as ELP4. Other genes that were suggested to be associated with RE also play vital roles in other epileptic disorders, including BDNF, KCNQ2, KCNQ3, DEPDC5, RBFOX1/3, and GABAA-R. In addition to particular genes, recurrent copy number variants (CNVs) in specific loci have also been found to be related to seizures [30] [31] [32] . A large number of CNVs were found in a cohort of 47 RE patients [33] . After exclusion of non-recurrent CNVs that were not clinically necessary, the recurrent 16p11.2 microduplication was the first to be associated with RE. Furthermore, Reinthaler et al. [34] ; revealed that 1.53% of patients carried the variants, which highlighted a significant association of this locus in RE/ARE patients (7/440 RE/ARE patients versus 32/65046 controls, p = 7.53 Â 10
À9
). Moreover, no enrichment of the 16p11.2 microduplication was found in other common epilepsy syndromes, such as genetic generalized epilepsy (GGE) or mesial temporal lobe epilepsies (mTLEs), suggesting its selective contribution to RE/ARE. Two of the families carried other variants of known RE-related genes, GRIN2A and DEPDC5 in addition to the 16p11 microduplication. However, in the case of GRIN2A, the specific EEG trait segregated with the GRIN2A mutation, and the 16p11.2 microduplication did not seem to be necessary for the phenotype. Interestingly, 16p11.2 is also a known risk factor for ASD [35] ; however, its pleiotropic nature in RE/ARE and ASD has remained unclear until now. The paroxysmal kinesigenic dyskinesia (PKD)-related gene PRRT2, which is localized in 16p11.2, appeared to be a putative genetic factor of RE. Che et al. performed a comprehensive genetic mutation screening of the PRRT2 gene in a cohort of 53 sporadic RE patients, and no variant was found, indicating that the PRRT2 mutations might not be associated with RE [36] .
Brain-derived neurotrophic factor: BDNF
BDNF is located on the short arm of chromosome 11, encoding a protein that is a member of the neutrophin family of growth factors. There is much evidence of BDNF's effect on the central nervous system, and its role as a putative cellular effector of recurrent epileptic seizures in the dentate gyrus [37] . However, the most studied and promising variant of BDNF in the field of seizures, p.Val66Met, was not associated with temporal lobe epilepsy or febrile seizure in two different studies [38, 39] . In the only casecontrol study of the p.Val66Met polymorphism of BDNF in RE, Gkampeta et al. found no p.Val66Met variant in 60 RE patients, suggesting that BDNF p.Val66Met does not contribute significantly to RE [40] . However, other polymorphisms in BDNF have not been studied and warrant further investigation.
DEP domain containing 5: DEPDC5
DEPDC5 is located on chromosome 22 and encodes a member of the IML1 family of proteins that play important roles in the regulation of the mechanistic target of the rapamycin complex 1 (mTORC1) pathway. Aberrant activation of the mTOR1 pathway alters cortical brain development dramatically and is associated with epilepsy [41] . Mutations in DEPDC5 were first identified as a crucial contributor in a variety of non-lesional autosomal dominant focal epilepsies, including familial focal epilepsy with variable foci (FFEVF) [42] , autosomal dominant nocturnal frontal epilepsy (ADNFLE) [43] , and other rare genetic focal epilepsies [44] . Later, Lal et al. identified seven rare variants in 207 probands with RE, four of which were predicted to be severely damaging by in silico tools. However, the variants were all present in unaffected family members, indicating a rare, but potentially important role of DEPDC5 in RE with incomplete penetrance [45] . Van Kranenburg et al. further investigated three of the reported variants, p.Val90Ile, p.Val272Leu, and p.Ser1162Gly, with regards to DEPDC5 function. Their in vitro effects on TORC1, GATOR-1 complex formation, and their interactions with active RAG-A-RAG-C complexes were assessed; however, none of them showed pronounced differences compared with wild-type DEPDC5 [46] . Thus, the pathogenicity of DEPDC5 variants still requires further investigation.
Elongator Protein Complex 4: ELP4
ELP4 was located to 11p13 by fine mapping after the identification of linkage to CTS. ELP4 is one of the six subunit of ELP. There is little information on the mechanism of epileptogenesis for ELP4. One of the presumed functions of aberrant ELP4 is dysregulation of the maturation of cortical projection neurons [47, 48] . Moreover, in humans, the gene locus of ELP4 is in close proximity to BDNF, which enhances the possibility that BDNF and ELP4 act together in RE [49] . Several polymorphic markers in the ELP4 gene showed association with the CTS phenotype; however, no causative variant was identified [28] . Later, the role of ELP4 in RE was questioned by several reexamination analyses. A study comprising 60 RE patients and 60 controls tested two single nucleotide polymorphisms (SNPs) in ELP4, rs964112 and rs11031434, discovered in a previous study, but found no significant difference between the cases and controls [40] . Reinthaler et al. performed whole exome sequencing to analyze ELP4 in 204 patients (182 RE and 22 ARE). Four missense variants were identified; however, in silico prediction indicated that none of them were damaging, and their frequencies were not different from those obtained for healthy controls in the public database.
Furthermore, a previous association analysis of 10 SNPs also failed to achieve nominal significance [50] . However, a recent study of the ELP4-PAX6 locus in RE families found the noncoding SNP rs662702 in PAX6 was linked with increased risk of CTS (odds ratio = 12. genes encoding GABA A -R subunits (a1-a5, b1-b3, g1-g3, d, e, p, t, r1-r3) was identified in mammals in the 1990s, which assemble pentameric GABA A -R in different combinations. The most common synaptic GABA A -Rs combination comprises two a1-a3 subunits, two b2-b3 subunits, and one g2 subunit, which are encoded by GABRA1-3, GABRB2-3, and GABRG2, respectively. The types and locations of mutations in GABA A -Rs vary substantially, and are typically associated with different epileptic syndromes [52] . Multiple mechanisms, including impaired trafficking, cell surface expression, and post-synaptic clustering by diffusion dynamics in the plasma membrane of GABA A -R, are believed to play vital roles in epileptogenesis, given the robust evidence on the enhanced the imbalances of excitatory and inhibitory neurotransmission in epilepsy [53] . Various mutations in GABA A -R subunit genes have been identified in a wide spectrum of epilepsies [54, 55] . Reinthaler et al. [56] sequenced the exome of 18 GABA A -R genes in 204 unrelated RE/ARE patients (182 RE and 22 ARE), and the enrichment of rare variants was detected in GABRG2. Five rare variants were identified in GABRG2, which differed significantly in patients (5/204, 2.45%) compared with controls (1 of 723, 0.14%). Subsequent comprehensive in vitro molecular and functional characterization assessment in vitro revealed altered GABA A -R function in two of five missense mutations of GABRG2: reduced surface expression of p.Gly257Arg and decreased GABA-evoked currents for p.Arg323Gln. This study was the first to provide evidence that variants in GABRG2 might increase the risk of RE and ARE.
Glutamate ionotropic receptor NMDA type subunit 2A: GRIN2A
The GRIN2A gene, which is located at 16p13.2, encodes the GluN2A subunit of the NMDA receptor (NMDAR), a ligand-gated ion channel that has important roles in brain development and function [57] . After the discovery of deletions in 16p13.2p13.13 spanning the GRIN2A gene, in three patients with seizure disorders of the Rolandic area, intellectual disability, and dysmorphic features [58] , much attention has been paid to this gene. The importance of GRIN2A in RE and related syndromes was further enhanced by the identification of nine additional patients with a history of epilepsy and/or a respective abnormal EEG pattern, and intellectual disability [59, 60] . The main evidence in favor of GRIN2A as an underlying gene for RE and ARE was the identification of various mutations or microdeletions of GRIN2A in a cohort with idiopathic focal epilepsy with Rolandic spikes, namely RE, ABPE, LKS and CSWS, with a higher frequency of variants in the more severe phenotypes, ranging from 4.9% (12/245) in RE to 17.6% (9/ 51) in CSWS syndrome [61] . Lesca et al. also confirmed that GRIN2A plays a crucial role in epilepsy in the RE spectrum, especially at the severe end of LKS/CSWS/EAS, and only 0.3% (1/277) of patients with RE in the cohort had the GRIN2A variant [62] . Carvill et al. found that among 81 RE patients, none harbored GRIN2A variants; however, 9% (4/44) of patients with epileptic encephalopathy with epilepsy-aphasia syndromes (EAS) carried pathogenic GRIN2A variants [63] .
To date, GRIN2A mutations have been reported in a small number of individuals with a wide spectrum of diseases other than the RE spectrum, including autism [64] , epileptic encephalopathy, and focal epilepsy without EAS or CTS [65] [66] [67] [68] . It is accepted that mutations in GRIN2A are involved preferentially in RE and ARE, especially in ARE. In RE, both single nucleotide variations (SNVs) and CNVs of GRIN2A were identified, and the type and location of the variants were not correlated with the clinical manifestation [69] . Meanwhile, some RE/ARE patients not only carried the variants of GRIN2A, but also were affected by mutations in SRPX2 (Sushi-Repeat containing protein) [62] and 16p11.2 microduplication [34] . The interplay of these genes has not been determined.
The mechanism of mutated GRIN2A in epilepsy is largely unknown. Swanger et al. investigated the mechanisms by which 17 rare variants in GRIN2A identified in ClinVar, HGMD, and published reports dysregulated NMDAR activity in vitro, and showed an overall impact on synaptic and non-synaptic NMDAR function [70] .
Ser1459Gly. Of interest, both gain-and loss-of-function variants were found in GRIN2A, which were related to similar genotypes, indicating a multifaceted and conflicting consequences of GRIN2A variants which requires further research. In addition, Endele et al. permeability [60, 71] . Although the GRIN2A mutation rate is higher in the severe end of the RE/ARE spectrum, GRIN2A is still the most relevant gene for RE; however, its prevalence and expression in RE, as well as the underlying mechanism, remain to be determined.
1.2.6. Potassium voltage-gated channel subfamily Q members 2 and 3: KCNQ2 and KCNQ3 KCNQ2 and KCNQ3 are located on chromosome 20 and 8 respectively, and encode the a subunits of potassium channels (the voltage-gated Kv7.2 and Kv7.3 channels, respectively). In neurons, KCNQ2 and KCNQ3 subunits represent the molecular basis of the M-current (I KM ), with a critical role in spike-frequency adaptation and control of neuronal excitability [72] . Defects in these genes are a cause of benign familial neonatal convulsions type 1 (BFNC) [73] [74] [75] . Although BFNC typically has an onset around day 3 after birth, and almost completely remits after several weeks 16% of these cases have seizures later in life [76] . Mutations in KCNQ2 were discovered in two patients with familial BFNC who developed RE or respective EEG traits later in life [77, 78] , and later in a sporadic case of RE without neonatal convulsion [79] , suggesting that the KCNQ2 defect is responsible for the early appearance of RE. The RNA binding proteins, fox-1(RBFOX) proteins, that is, the three homologs RBFOX1, RBFOX2, RBFOX3, are encoded by RBFOX genes. RBFOXs are high-level, neuron-specific splicing factors that regulate certain important epilepsy candidate genes including SCL1A3 and KCNQ2 [81] ; therefore, it is not surprising that mutations disrupting RBFOXs have been found in several neurodevelopmental and neuropsychiatric disorders, including ASD [82] [83] [84] [85] , mental retardation [86] , and epilepsy [86] . RBFOX1 mutations were found to be enriched significantly in GGE [87] and sporadic focal epilepsy [88] . Recently, Lal et al. explored rare microdeletions and exonic variations in RBFOX1/2/3. Among 289 RE patients screened for CNVs, only one (0.34%) carried a hemizygous deletion in both RBFOX1 and RBFOX3. Meanwhile, 1.2% (3/242) of patients harbored 3 different rare variants of RBFOX1 or RBFOX3, which were also identified in the family members with typical CTS without clinical seizures [89] . The impact of the identified CNVs of RBFOX1 and RBFOX3 on RBFOX expression or function is unclear, but pathogenic CNVs of RBFOX1 were generally presumed to reduce RBFOX1 expression. Meanwhile, the SNVs were unlikely to be directly causative, but were presumed to co-segregate with other rare variants indirectly, influencing RBFOX1 expression or regulation. These studies indicated that the RBFOX1/3 variants might be risk factors for RE; however, this hypothesis requires additional familial confirmation. In addition, further functional studies of the affected carriers would be highly valuable.
Discussion
Even though there is considerable debate about the genetic basis of RE, researchers are still making remarkable progress in investigating its potential mechanisms. Recent discoveries have increased our understanding of the multifactorial genetic inheritance in the RE/ARE spectrum. This involves genomic heterogeneity where mutations in different genes cause the same phenotype, and phenotypic variability where mutations in the same gene cause a variety of epilepsies with a wide spectrum of clinical manifestations. Incomplete penetrance was noted for almost every rare variant and for most CNVs responsible for RE. These findings raise questions as to how variants can be predisposed to both RE and other neurodevelopmental or neuropsychiatric disorders, including ASD and mental retardation, and how different genes cooperate in the penetrance and phenotype of RE/ARE. However, some limitations of these studies should be considered. First, except for GRIN2A and ELP4, most genes were identified in other diseases first and then explored in RE. The pathogenicity of most reported variants in RE was only based on the enrichment of corresponding variants and functional predictions by in silico algorithms suggested by a single study. Most of these findings still lack reexamination or could not be replicated in other cohorts. Expanded sample sizes and more diverse ethnic groups are needed to provide further evidence for the involvement of the reported variants. Second, some in vitro studies have provided preliminary evidence of aberrant protein function; however, animal models incorporating these disease-causing mutations are still lacking. Third, none of these studies can explain how the mutated genes exert the age-dependence phenomenon observed in RE. In the future, whole exome/genome sequencing and studies focusing on the epigenetics of RE, including non-coding RNA and methylation of DNA, might help to establish connections between genetic variations, mechanisms of relevant protein dysregulation, and the disease phenotype of RE.
Conclusions
In summary, despite the emergence of new genes and related loci, researchers generally agree that the genetic basis of RE/ARE is polygenic and complex, and that investigators must look beyond traditional genetic approaches and consider the interaction of environmental factors or other genes. Even though the genetic complexities of epilepsy may present challenges when applied in the clinical setting, it is obvious that a detailed understanding of genetic epilepsy mechanisms could lead to the development of novel anticonvulsant therapies that target epileptogenesis in common epilepsy.
